Darbepoetin, effective treatment of anaemia in paediatric patients with chronic renal failure

Pediatric Nephrology

Volumn 22, Issue 5, 2007, Pages 708-714

  André, Jean Luc ^a   Deschênes, Georges ^b   Boudailliez, Bernard ^c   Broux, Françoise ^d   Fischbach, Michel ^e   Gagnadoux, Marie France ^f   Horen, Benjamin ^g   Lahoche Manucci, Annie ^h   Macher, Marie Alice ⁱ   Roussel, Bernard ^j   Tsimaratos, Michel ^k   Loirat, Chantal ⁱ  

^a HÔPITAL D ENFANTS   (France)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d HÔPITAL CHARLES NICOLLE   (France)

^e HÔPITAL DE HAUTEPIERRE   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g HÔPITAL DES ENFANTS   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ HÔPITAL ROBERT DEBRÉ   (France)

^j AMERICAN MEMORIAL HOSPITAL   (France)

^k TIMONE HOSPITAL   (France)

more..

Author keywords

Anaemia; Chronic kidney disease; Chronic renal failure; Darbepoetin alfa; Dialysis; Haemoglobin; Paediatrics; r HuEPO

Indexed keywords

FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; THROMBOSIS;

ADOLESCENT; ANEMIA; CHILD; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FERRITINS; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SAFETY;

EID: 34247871271     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-006-0402-1     Document Type: Article

References (26)

1. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE (1996) The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28:53-61
2. Brandt JR, Avner ED, Hickman RO, Watkins SL (1999) Safety and efficacy of erythropoietin in children with chronic renal failure. Pediatr Nephrol 13:143-147
3. Jabs K, Harmon WE (1996) Recombinant human erythropoietin therapy in children on dialysis. Adv Ren Replace Ther 3:24-36
4. McDougall IC, Davies R, Hutton R, Cavill I, Lewis N, Coles G, Williams J (1990) The treatment of renal anemia in CAPD patients with recombinant human erythropoietin. Nephrol Dial Transplant 5:950-955
5. Burke JR (1995) Low dose subcutaneous recombinant erythropoietin in children with chronic renal failure. Pediatr Nephrol 9:558-561
6. Walter T, De Andraca T, Chadud P, Perales C (1989) Iron deficient anemia: Adverse effects on infant psychomotor development. Pediatrics 84:7-17
7. Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B (2000) The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: Results from a randomized controlled multicentre trial. Nephrol Dial Transplant 15:2014-2019
8. Locatelli F, Baldamus CA, Villa G, Ganea A, Martin de Francisco AL (2002) Once-weekly compared with three-times-weekly subcutaneous epoetin β: Results from a randomized, multicenter, therapeutic-equivalence study. Am J Kidney Dis 40:119-125
9. McDougall IC (2002) Once-weekly erythropoietic therapy: Is there a difference between the available preparations? Nephrol Dial Transplant 17:2047-2051
10. Brandt JR, Avner ED, Hickman RO, Watkins SL (1999) Safety and efficacy of erythropoietin in children with chronic renal failure. Pediatr Nephrol 13:143-147
11. Chavers BM, Roberts TL, Herzog CA, Collins AJ, St Peter WL (2004) Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients. Kidney Int 65:266-273
12. Egrie JC, Browne JK (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16:3-13
13. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA (2003) Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290-299
14. Lerner G, Kale AS, Warady BA, Jabs K, Bunchman TE, Heatherington A, Olson K, Messer-Mann L, Maroni BJ (2002) Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol 17:933-937
15. Brunkhost R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T (2004) Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 19:1224-1230
16. Bristoyiannis G, Germanos N, Grekas D, Hatzidimitrou C, Iatrou C, Memmos D, Moutafis S, Papachristoforou K, Papadoniou A, Pappas M, Sakellariou GA, Siamopoulos KC, Sombolos K, Stamatelou K, Stathakis CP, Stavgiannoudakis G, Stratigis S, Syrganis C, Tsakiris D, Valis D, Vlahojannis JG, Vlassopoulos D (2005) Unit dosing of DA for the treatment of anemia in patients with end-stage renal disease being switched from recombinant human erythropoietin: Results of a phase IIIb, 27-week, multicenter, open-label study in Greek patients. Curr Ther Res Clin Exp 66:195-210
17. De Palo T, Giordano M, Palumbo F, Bellantuono R, Messina G, Colella V, Caringella AD (2004) Clinical experience with darbepoetin alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol 19:337-340
18. Geary DF, Keating LE, Vigneux A, Stephens D, Hébert D, Harvey EA (2005) Darbepoetin alfa (Aranesp) in children with chronic renal failure. Kidney Int 68:1759-1765
19. Warady BA, Arar MY, Lerner G, Nakanishi AM, Stehman-Breen C (2006) Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Pediatr Nephrol 21:1144-1152
20. Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker N, Gray SJ, European/Australian NESP 970200 Study Group (2002) Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 62:2167-2175
21. Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J (2003) Treatment of anemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEPO). Nephrol Dial Transplant 18:362-369
22. Macdougall IC (2001) Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int Suppl 8:S67-S72
23. Ifudu O, Cohen LS, Mayers JD, Joseph A, Delano BG, Friedman EA (2001) Residual renal function modulates response to erythropoietin in chronic renal insufficiency. Dial Transplant 30:344-354
24. Frankenfield DL, Neu AM, Warady BA, Fivush BA, Johnson CA, Brem AS (2003) Anemia in pediatric hemodialysis patients: Results from the 2001 ESRD Clinical performance measures project. Kidney Int 64:1120-1124
25. KDOQI National Kidney Foundation (2006) III Clinical Practice recommendations for anaemia in chronic kidney disease in children. Am J Kidney Dis 47:S86-S108
26. Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, Roger S (2004) Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 24:453-460